Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Unity Biotechnology

DB:9U9
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
9U9
DB
$262M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
9U9 Share Price and Events
7 Day Returns
4.4%
DB:9U9
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-25.3%
DB:9U9
-13.2%
DE Biotechs
-20.9%
DE Market
9U9 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Unity Biotechnology (9U9) 4.4% 1.9% -16.6% -25.3% - -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 9U9 underperformed the Biotechs industry which returned -13.2% over the past year.
  • 9U9 underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

9U9 Value

 Is Unity Biotechnology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Unity Biotechnology. This is due to cash flow or dividend data being unavailable. The share price is €5.415.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Unity Biotechnology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Unity Biotechnology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:9U9 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.88
NasdaqGS:UBX Share Price ** NasdaqGS (2020-04-03) in USD $5.51
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Unity Biotechnology.

DB:9U9 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:UBX Share Price ÷ EPS (both in USD)

= 5.51 ÷ -1.88

-2.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unity Biotechnology is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Unity Biotechnology is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Unity Biotechnology's expected growth come at a high price?
Raw Data
DB:9U9 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Unity Biotechnology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Unity Biotechnology's assets?
Raw Data
DB:9U9 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.56
NasdaqGS:UBX Share Price * NasdaqGS (2020-04-03) in USD $5.51
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:9U9 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:UBX Share Price ÷ Book Value per Share (both in USD)

= 5.51 ÷ 2.56

2.16x

* Primary Listing of Unity Biotechnology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unity Biotechnology is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Unity Biotechnology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Unity Biotechnology has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

9U9 Future Performance

 How is Unity Biotechnology expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Unity Biotechnology expected to grow at an attractive rate?
  • Unable to compare Unity Biotechnology's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Unity Biotechnology's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Unity Biotechnology's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:9U9 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:9U9 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:9U9 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 -92
2023-12-31 -121
2022-12-31 0 -113 1
2021-12-31 0 -103 2
2020-12-31 0 -35 2
2020-04-06
DB:9U9 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -72 -82
2019-09-30 -70 -86
2019-06-30 -67 -83
2019-03-31 -65 -79
2018-12-31 -57 -76
2018-09-30 1 -55 -67
2018-06-30 1 -51 -60
2018-03-31 1 -42 -52
2017-12-31 1 -38 -45

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Unity Biotechnology is high growth as no earnings estimate data is available.
  • Unable to determine if Unity Biotechnology is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:9U9 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Unity Biotechnology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9U9 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06
DB:9U9 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.88
2019-09-30 -2.03
2019-06-30 -1.97
2019-03-31 -2.08
2018-12-31 -2.70
2018-09-30 -3.59
2018-06-30 -6.61
2018-03-31 -15.78
2017-12-31 -13.97

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Unity Biotechnology will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Unity Biotechnology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Unity Biotechnology has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

9U9 Past Performance

  How has Unity Biotechnology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Unity Biotechnology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Unity Biotechnology does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Unity Biotechnology's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Unity Biotechnology's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Unity Biotechnology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Unity Biotechnology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9U9 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -82.18 20.05
2019-09-30 -86.07 19.47
2019-06-30 -82.70 18.16
2019-03-31 -79.03 17.04
2018-12-31 -76.40 16.02
2018-09-30 1.38 -67.03 14.27
2018-06-30 1.38 -60.43 12.36
2018-03-31 1.38 -51.86 11.00
2017-12-31 1.38 -44.66 9.62
2016-12-31 -30.40 5.14

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Unity Biotechnology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Unity Biotechnology has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Unity Biotechnology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Unity Biotechnology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Unity Biotechnology has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

9U9 Health

 How is Unity Biotechnology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Unity Biotechnology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unity Biotechnology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Unity Biotechnology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Unity Biotechnology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -18498.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Unity Biotechnology Company Filings, last reported 3 months ago.

DB:9U9 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 120.71 0.00 127.49
2019-09-30 114.72 0.00 112.97
2019-06-30 127.05 0.00 128.00
2019-03-31 146.60 0.00 150.20
2018-12-31 160.69 0.00 171.14
2018-09-30 179.52 0.00 177.81
2018-06-30 195.07 0.00 185.97
2018-03-31 130.28 0.00 134.04
2017-12-31 90.84 0.00 86.51
2016-12-31 89.55 0.00 89.29
  • Unity Biotechnology's level of debt (-0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Unity Biotechnology's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Unity Biotechnology has sufficient cash runway for 1.7 years based on current free cash flow.
  • Unable to confirm if Unity Biotechnology has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Unity Biotechnology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Unity Biotechnology has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

9U9 Dividends

 What is Unity Biotechnology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Unity Biotechnology dividends. Estimated to be 0% next year.
If you bought €2,000 of Unity Biotechnology shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Unity Biotechnology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Unity Biotechnology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:9U9 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:9U9 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 2.00
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Unity Biotechnology has not reported any payouts.
  • Unable to verify if Unity Biotechnology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Unity Biotechnology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Unity Biotechnology has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Unity Biotechnology's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Unity Biotechnology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Unity Biotechnology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Unity Biotechnology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

9U9 Management

 What is the CEO of Unity Biotechnology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Anirvan Ghosh
TENURE AS CEO 0.1 years
CEO Bio

Dr. Anirvan Ghosh, Ph.D. serves as Chief Executive Officer of Unity Biotechnology, Inc. since March 20, 2020. Dr. Ghosh had been Senior Vice President of Research and Early Development at Biogen Inc. since April 2017. Dr. Ghosh joined Biogen from E-Scape Bio, where he served as Chief Scientific Officer. Prior to heading discovery efforts for Alzheimer's disease and neurodegenerative disorders at E-Scape Bio, he served as Vice President, Global Head of Neuroscience Discovery and Biomarkers at Roche. In this capacity, Dr. Ghosh led research and drug discovery for programs addressing neurodegenerative diseases as well as neurodevelopmental and psychiatric disorders. Prior to joining industry, Dr. Ghosh served as a Professor On The Neuroscience Faculties of the Johns Hopkins University and the University of California, San Diego. His academic research has focused on understanding how connections in the brain are established during development and how these connections may be affected in neurodevelopmental disorders. He is the author of more than 90 scientific publications. Dr. Ghosh served as founding CSO at E-Scape Bio, and Global Head of Neuroscience Discovery and Biomarkers at Roche. Dr. Ghosh served as a professor of neuroscience at Johns Hopkins University and the University of California, San Diego. Dr. Ghosh received a BS in Physics from the California Institute of Technology, a Ph.D. in Neuroscience from Stanford University and postdoctoral training at Harvard Medical School.

CEO Compensation
  • Insufficient data for Anirvan to compare compensation growth.
  • Insufficient data for Anirvan to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Unity Biotechnology management team in years:

4.3
Average Tenure
50.5
Average Age
  • The tenure for the Unity Biotechnology management team is about average.
Management Team

Ned David

TITLE
Co-Founder
COMPENSATION
$3M
AGE
51
TENURE
4.3 yrs

Jamie Dananberg

TITLE
Chief Medical Officer
COMPENSATION
$952K
AGE
61
TENURE
4.3 yrs

Anirvan Ghosh

TITLE
Chief Executive Officer
TENURE
0.1 yrs

Jan van Deursen

TITLE
TENURE
9.3 yrs

Judy Campisi

TITLE
TENURE
9.3 yrs

Daohong Zhou

TITLE
TENURE
9.3 yrs

Bob Goeltz

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
46
TENURE
2.6 yrs

Douglas Rich

TITLE
Senior Vice President of Operations
AGE
50
TENURE
3 yrs

Dan Marquess

TITLE
Chief Scientific Officer
AGE
50
TENURE
4.3 yrs

Tammy Tompkins

TITLE
General Counsel & Corporate Secretary
AGE
54
TENURE
2.8 yrs
Board of Directors Tenure

Average tenure and age of the Unity Biotechnology board of directors in years:

4.7
Average Tenure
52
Average Age
  • The tenure for the Unity Biotechnology board of directors is about average.
Board of Directors

Keith Leonard

TITLE
Chairman
COMPENSATION
$3M
AGE
57
TENURE
4.3 yrs

Ned David

TITLE
Co-Founder
COMPENSATION
$3M
AGE
51
TENURE
8.4 yrs

Graham Cooper

TITLE
Independent Director
COMPENSATION
$168K
AGE
49
TENURE
3 yrs

David Lacey

TITLE
Independent Director
COMPENSATION
$286K
AGE
67
TENURE
2.2 yrs

Paul Berns

TITLE
Lead Independent Director
COMPENSATION
$933K
AGE
52

Bob Nelsen

TITLE
Independent Director
AGE
57
TENURE
8.4 yrs

Kristina Burow

TITLE
Independent Director
COMPENSATION
$552K
AGE
46
TENURE
8.4 yrs

Cami Samuels

TITLE
Independent Director
COMPENSATION
$551K
AGE
48
TENURE
5.1 yrs

Margo Roberts

TITLE
Independent Director
COMPENSATION
$534K
AGE
64
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Unity Biotechnology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Unity Biotechnology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

9U9 News

Simply Wall St News

9U9 Company Info

Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company’s lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Details
Name: Unity Biotechnology, Inc.
9U9
Exchange: DB
Founded: 2009
$243,170,748
47,613,143
Website: http://www.unitybiotechnology.com
Address: Unity Biotechnology, Inc.
3280 Bayshore Boulevard,
Suite 100,
Brisbane,
California, 94005,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS UBX Common Stock Nasdaq Global Select US USD 03. May 2018
DB 9U9 Common Stock Deutsche Boerse AG DE EUR 03. May 2018
LSE 0YC0 Common Stock London Stock Exchange GB USD 03. May 2018
Number of employees
Current staff
Staff numbers
98
Unity Biotechnology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 01:17
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/03/11
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.